1887

Abstract

Epstein—Barr virus (EBV) is a major human pathogen for which the development of an effective vaccine remains an important goal. Rabbits were immunized with one of a set of 10 fusion proteins representing protein fragments from the EBV receptor-binding ligand and candidate subunit vaccine gp340. Sera from recipients of fragments from the amino-terminal half of the polypeptide chain bound gp340 in Western blot assays and ELISA but were not virus-neutralizing. The fine epitope specificity of these sera, and of EBV-neutralizing rabbit sera raised against whole EBV and gp340-containing immune-stimulating complexes, were assessed in a peptide ELISA. All but two of these sera bound peptides located between positions 236 and 327 in the 907 amino acids of the gp340 polypeptide chain. Among these it was possible to identify regions containing candidate virus-neutralizing B cell epitopes. The use of a gp340 fusion protein affinity column to isolate antibodies from EBV-neutralizing rabbit sera specific for this region suggests the presence of both continuous and discontinuous B cell epitopes with potential roles in EBV neutralization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-6-1409
1992-06-01
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/6/JV0730061409.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-6-1409&mimeType=html&fmt=ahah

References

  1. Alexander S., Elder J. H. 1984; Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226:1328–1330
    [Google Scholar]
  2. Barlow D. J., Edwards M. G., Thornton J. M. 1986; Continuous and discontinuous antigenic determinants. Nature, London 322:747–748
    [Google Scholar]
  3. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kezdy F., Kieff E. 1985; Two major outer envelope glycoproteins of Epstein–Barr virus are encoded by the same gene. Journal of Virology 54:665–674
    [Google Scholar]
  4. Bertoni G., Kostyal D. A., Reisert P. S., Humphreys R. E., Sairenji T. 1990; Synthetic peptides to identify antigenic determinants on Epstein–Barr virus gp350/220. Intervirology 31:290–294
    [Google Scholar]
  5. Blundell T. L., Sibanda B. L., Sternberg M. J. E., Thornton J. M. 1987; Knowledge-based prediction of protein structures and the design of novel molecules. Nature, London 326:347–352
    [Google Scholar]
  6. Celada F., Sercarz E. E. 1988; Preferential pairing of T‒B specificities in the same antigen: the concept of directional help. Vaccine 6:94–98
    [Google Scholar]
  7. Cleary M. L., Epstein M. A., Finerty S., Dorfman R. F., Bornkamm G. W., Kirkwood J. K., Morgan A. J., Sklar J. 1985; Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228:722–724
    [Google Scholar]
  8. Correa I., Gebauer F., Bullido M. J., Suñé C., Baay M. F. D., Zwaagstra K. A., PosthumuS W. P. A., Lenstra J. A., Enjuanes L. 1990; Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus. Journal of General Virology 71:271–279
    [Google Scholar]
  9. DE Schryver A., Klein G., Hewetson J., Rocchi G., Henle W., Henlé G., Moss D. J., Pope J. H. 1974; Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). International Journal of Cancer 13:353–362
    [Google Scholar]
  10. Epstein M. A., Morgan A. J., Finerty S., Randle B. J., Kirkwood J. K. 1985; Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, London 318:287–289
    [Google Scholar]
  11. Epstein M. A., Randle B. J., Finerty S., Kirkwood J. K. 1986; Not all potentially neutralizing, vaccine-induced antibodies to Epstein–Barr virus ensure protection of susceptible experimental animals. Clinical and Experimental Immunology 63:485–490
    [Google Scholar]
  12. Francis M. J., Hastings J. Z., Syred A. D., McGinn B., Brown F., Rowlands D. J. 1987; Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature, London 330:168–170
    [Google Scholar]
  13. Hansen J. E. S., Clausen H., Nielsen C., Teglbjaerg L. S., Hansen L. L., Nielsen C. M., Dabelsteen E., Mathiesen L., Hakomori S. I., Nielsen J. O. 1990; Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gpl20 may be a target for virus neutralization. Journal of Virology 64:2833–2840
    [Google Scholar]
  14. Ho D. D., McKeating M. A., Li X. L., Moudgil T., Daar E. S., Sun N. C., Robinson J. E. 1991; Conformational epitope on gpl20 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. Journal of Virology 65:489–493
    [Google Scholar]
  15. Hoffman G. J., Lazarowitz S. G., Hayward S. D. 1980; Monoclonal antibody against a 250, 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proceedings of the National Academy of Sciences, U.S.A. 77:2979–2983
    [Google Scholar]
  16. Javaherian K., Langlois A. J., Larosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. 1990; Broadly neutralizing antibodies elicited by the hyper-variable neutralizing determinant of HIV-1. Science 250:1590–1593
    [Google Scholar]
  17. Jemmerson R. 1987; Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies. Proceedings of the National Academy of Sciences, U.S.A. 84:9180–9184
    [Google Scholar]
  18. Jondal M. 1976; Antibody-dependent cellular cytotoxicity (ADCC) against Epstein–Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis. Clinical and Experimental Immunology 25:1–5
    [Google Scholar]
  19. Khyatti M., Patel P. C., Stefanescu I., Menezes J. 1991; Epstein–Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. Journal of Virology 65:996–1001
    [Google Scholar]
  20. Milich D. R. 1988; T- and B-cell recognition of hepatitis B viral antigens. Immunology Today 9:380–386
    [Google Scholar]
  21. Miller G. 1990; Epstein–Barr virus: biology, pathogenesis and medical aspects. In Virology 2nd edn pp 1921–1958 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
    [Google Scholar]
  22. Modrow S., Kleinhaus K., Marschall M., Hoflacher B., Wolf H. 1988; Use of synthetic oligopeptides for the identification and characterization of Epstein–Barr viral membrane proteins. In Epstein–Barr Virus and Human Disease pp 235–239 Edited by Ablashi D.V, Faggioni A., Krueger G. R. F., Pagano J. S., Pearson G. R. Clifton: Humana;
    [Google Scholar]
  23. Morgan A. J., Smith A. R., Barker R. N., Epstein M. A. 1984; A structural investigation of the Epstein–Barr (EB) virus membrane antigen glycoprotein, gp340. Journal of General Virology 65:397–404
    [Google Scholar]
  24. Morgan A. J., Finerty S., Lovgren K., Scullion F. T., Morein B. 1988a; Prevention of Epstein–Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. Journal of General Virology 69:2093–2096
    [Google Scholar]
  25. Morgan A. J., Mackett M., Finerty S., Arrand J. R., Scullion F. T., Epstein M. A. 1988b; Recombinant vaccinia virus expressing Epstein–Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. Journal of Medical Virology 25:189–195
    [Google Scholar]
  26. Morgan A. J., Allison A. C., Finerty S., Scullion F. T., Byars N. E., Epstein M. A. 1989; Validation of a first-generation Epstein–Barr virus vaccine preparation suitable for human use. Journal of Medical Virology 29:74–78
    [Google Scholar]
  27. Nemerow G. R., Houghten R. A., Moore M. D., Cooper N. R. 1989; Identification of an epitope in the major envelope protein of Epstein–Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369–377
    [Google Scholar]
  28. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982; Purified Epstein–Barr virus M r 340, 000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proceedings of the National Academy of Sciences, U.S.A. 79:7504–7508
    [Google Scholar]
  29. Pearson G. R., Qualtière L. F. 1978; Papain solubilization of the Epstein–Barr virus-induced membrane antigen. Journal of Virology 28:344–351
    [Google Scholar]
  30. Pearson G. R., Qualtière L. F., Klein G., Norin T., Bal I. S. 1979; Epstein–Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt’s lymphoma. International Journal of Cancer 24:402–406
    [Google Scholar]
  31. Pither R. J., Zhang C. X., Shiels C., Tarlton J., Finerty S., Morgan A. J. 1992; Mapping of B cell epitopes on the polypeptide chain of the Epstein–Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. Journal of Virology 66:1246–1251
    [Google Scholar]
  32. Qualtière L. F., Chase R., Vroman B., Pearson G. R. 1982; Identification of Epstein–Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Proceedings of the National Academy of Sciences, U.S.A. 79:616–620
    [Google Scholar]
  33. Qualtière L. F., Decoteau J. F., Hassan Nasr-El-Din M. 1987; Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220. Journal of General Virology 68:535–543
    [Google Scholar]
  34. Rocchi G., Hewetson J., Henlé W. 1973; Specific neutralising antibodies in Epstein–Barr virus associated diseases. International Journal of Cancer 11:637–647
    [Google Scholar]
  35. Sairenh T., Bertoni G., Medveczky M. M., Medveczky P. G., Nguyen Q. V., Humphreys R. E. 1991; Inhibition of Epstein–Barr virus production in P3HR-1 cells by Epstein–Barr virus-seropositive human serum. Intervirology 32:37–51
    [Google Scholar]
  36. Tanner J., Whang Y., Sample J., Sears A., Kieff E. 1988; Soluble gp350/220 and deletion mutant glycoproteins block Epstein–Barr virus adsorption to lymphocytes. Journal of Virology 62:4452–4464
    [Google Scholar]
  37. Ulaeto D., Wallace L., Morgan A., Morein B., Rickinson A. B. 1988; In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. European Journal of Immunology 18:1689–1697
    [Google Scholar]
  38. Utz U., Britt W., Vugler L., Mach M. 1989; Identification of a neutralizing epitope on glycoprotein gp85 of human cytomegalovirus. Journal of Virology 63:1995–2001
    [Google Scholar]
  39. Wallace L. E., Wright J., Ulaeto D. O., Morgan A. J., Rickinson A. B. 1991; Identification of CD4+ T cell epitopes of the candidate Epstein–Barr virus vaccine glycoprotein gp340. Journal of Virology 65:3281–3828
    [Google Scholar]
  40. Yao Q. Y., Rowe M., Morgan A. J., Sam C. K., Prasad U., Dang H., Zeng Y., Rickinson A. B. 1991; Salivary and serum IgA antibodies to the Epstein–Barr virus glycoprotein gp340: incidence and potential for virus neutralization. International Journal of Cancer 48:45–50
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-73-6-1409
Loading
/content/journal/jgv/10.1099/0022-1317-73-6-1409
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error